Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

th year running and the awards ceremony will take place on November 18, 2009 in London.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to have been shortlisted for both the Biotech Company of the Year and Licensing Deal of the Year awards at this prestigious awards event. The nominations are a testament to the significant achievements and progress ThromboGenics has made over the last year. The Company is now in the best position to achieve its aim of becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines. We are very proud to be nominated amongst some of the most successful companies in the industry, and look forward to the results in November."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About Scrip World Pharmaceutical
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015  Indianapolis-based medical device manufacturer NICO Corporation ... of products including the BrainPath® and Myriad™ technologies ... brain abnormalities and then removing affected tissue. More ... than 50 institutions throughout the United ... included in 12 abstracts, three peer-reviewed publications, and ...
(Date:5/4/2015)... , May 4, 2015 Many of ... But for certain infants with rare, inherited mutations ... stark consequences of their impaired immune responses. ... have identified an important role for calcium signaling ... Mycobacterium tuberculosis, the bacterium causing tuberculosis (TB). ...
(Date:5/4/2015)... MEMPHIS, Tenn. , May 4, 2015 /PRNewswire-USNewswire/ ... have developed a significantly better computer tool for ... in many cancers but were difficult to identify ... the scientific journal Nature Methods . ... short for Copy Number Segmentation by Regression Tree ...
(Date:5/4/2015)... STONY BROOK, N.Y. , May 4, 2015 ... executed a $250,000 cooperative research and development agreement ... ) to advance the development of TRB-N0224 for ... companion animals, including dogs and cats.  Traverse Biosciences ... sublicense TRB-N0224 for the treatment and control of ...
Breaking Biology Technology:NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4
... , SEATTLE, Sept. 18 Omeros Corporation today ... million shares of its common stock. Omeros is a ... focused on inflammation and disorders of the central nervous system. ... the initial public offering is $10.00 to $12.00 per share. ...
... , EMERYVILLE, Calif., Sept. 17 ... today that, on September 15, 2009, it received a letter ... of NTI,s common stock has closed below $1.00 per share ... closing bid price below $1.00 per share is a deficiency ...
... , , EAST HANOVER, ... has approved Valturna(R) (aliskiren and valsartan) tablets, the first and only ... known as the renin angiotensin aldosterone system (RAAS), an important regulator ... is indicated for the treatment of high blood pressure in patients ...
Cached Biology Technology:Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 4Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 5Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 6Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 7
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/2/2015)... 2, 2015 At its 2015 ACMG Annual ... , the American College of Medical Genetics and ... to its Board.  Members of the ACMG Board of ... forming and advancing its policies and programs. ACMG is ... "It,s an eventful time in medical genetics and ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... of California, San Diego bioengineering professor Trey Idekera ... Society for Computational Biology,s Overton Prize. The Overton ... scientist who has already made a significant contribution ... Ideker is an Associate Professor of Bioengineering at ...
... National biobanks play a vital role in modern health research ... data, but they are expensive to run. Can we make ... borders on a larger scale? This is the theme of ... How can we maximize the value and use of ...
... A study to determine if patients with type 2 ... self-donated) stem cell infusions (ASC) and hyperbaric (above the ... and after ASC has found "significant benefits" in terms ... requirements." The combination therapy could decrease type 2 diabetes ...
Cached Biology News:UC San Diego bioengineering professor trey ideker wins 2009 Overton Prize 2UC San Diego bioengineering professor trey ideker wins 2009 Overton Prize 3Harmonizing biobank research: An achievable world-wide goal 2Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes 2
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
... GeneMaths XT is undoubtedly the most complete ... advanced concept of layers and subsets makes ... layers for different data outputs, for example ... etc., as well as different subsets of ...
...
...
Biology Products: